Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | PPARA | Q07869 | 5/20 | 0.59 |
| ▸ | PPARG | P37231 | 4/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415297 | 1.00 | ATM (0.70) | ATMPPARAPPARGACECTSK | |
| SCHEMBL23415300 | 1.00 | ATM (0.70) | ATMPPARAPPARGACECTSK | |
| SCHEMBL29901268 | 0.90 | ATM (0.67) | ATMPPARAPPARGACECTSK | |
| SCHEMBL9977267 | 0.90 | ATM (0.67) | ATMPPARAPPARGACECTSK | |
| SCHEMBL203084 | 0.90 | ATM (0.67) | ATMPPARAPPARGACECTSK | |
| SCHEMBL29865344 | 0.87 | ATM (0.60) | ATMPPARAPPARGACECTSK | |
| SCHEMBL23300975 | 0.85 | ATM (0.72) | ATMPPARAPPARGACECTSK | |
| SCHEMBL22536357 | 0.85 | ATM (0.72) | ATMPPARAPPARGACECTSK | |
| SCHEMBL13257949 | 0.85 | ATM (0.72) | ATMPPARAPPARGACECTSK | |
| SCHEMBL4705420 | 0.84 | ATM (0.51) | ATMPPARAPPARGACECTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294802-A1 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Universität Bielefeld (DE) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022175222-A1 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | UNIVERSITÄT BIELEFELD (DE) | 2022-08-25 | — | — | WO | disclosed |
| WO-2017189868-A1 | SERINE REPLACEMENT POLYMYXIN ANALOGUES USEFUL AS ANTIBIOTIC POTENTIATORS | SPERO OPCO (US) | 2017-11-02 | — | — | WO | disclosed |
| US-8476225-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110135604-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135604-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ATM 4174/4885PPARA 2980/4885PPARG 3490/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ATM 4174/4885PPARA 2980/4885PPARG 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.